UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
Current Report
 
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  August 17, 2012
 
 
ADVANCED MEDICAL ISOTOPE CORPORATION

(Name of registrant as specified in its charter)

Delaware
000-53497
80-0138937
(State or other jurisdiction of
Incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)
     
6208 W. Okanogan Ave.
 Kennewick, WA 99336
 
99336
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (509) 736-4000
 
 
N/A
 
 (Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 


 
1

 

Item 3.02  Unregistered Sales of Equity Securities.

On August 17, 2012, the Board of Directors granted a total of 3,000,000 shares of common stock to recipients who are officers, or consultants to the Company. The stock grants were fully vested upon grant. The recipients included: L. Bruce Jolliff, Chief Financial Officer, who was awarded 2,000,000 shares of common stock.

No underwriters were used for this transaction. As to this transaction, the Company relied upon the exemption from registration set forth in section 4(2) of the Securities Act of 1933, as amended, based upon the limited number of recipients, their relationship to the Company, and the private nature and other limitations of the transaction.














SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ADVANCED MEDICAL ISOTOPE CORPORATION
 
       
Date:  August 17, 2012
By:
/s/ James C. Katzaroff
 
 
Name:
James C. Katzaroff 
 
 
Title:
Chairman and Chief Executive Officer
 

2